New injection could shrink livers and ease pain in rare disease

NCT ID NCT05281328

First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 16 times

Summary

This study tests a new long-acting octreotide injection (CAM2029) in 71 adults with symptomatic polycystic liver disease. Participants receive weekly or biweekly injections or a placebo for 53 weeks to see if the drug reduces liver size and improves symptoms like bloating, pain, and fullness. The trial is active but no longer recruiting, and an open-label extension allows continued treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLYCYSTIC LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Bon Secours Richmond Community Hospital

    Richmond, Virginia, 23602, United States

  • Hannover Medical School

    Hanover, 30625, Germany

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Mount Sinai Hospital

    New York, New York, 10029, United States

  • Radboud UMC, Department of Gastroenterology and Hepatology

    Nijmegen, 6525 GA, Netherlands

  • The New York Presbyterian Hospital

    New York, New York, 10065, United States

  • Universitaetsklinikum Müenster

    Münster, 48149, Germany

  • University Hospitals KU Leuven

    Leuven, B-3000, Belgium

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75380, United States

  • Universitätsklinikum Leipzig

    Leipzig, 04103, Germany

Conditions

Explore the condition pages connected to this study.